Last reviewed · How we verify
NCT03547297
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
trial in Acute Hepatic Porphyria in 212 participants. Terminated before completion.
15 January 2019
Quick facts
| Lead sponsor | Alnylam Pharmaceuticals |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 212 |
| Start date | 29 May 2018 |
| Primary completion | 15 January 2019 |
| Estimated completion | 15 January 2019 |
| Sites | 12 locations across United States |
Conditions studied
- Acute Hepatic Porphyria — all drugs for Acute Hepatic Porphyria →
- Hepatic Porphyrias — all drugs for Hepatic Porphyrias →
- Acute Intermittent Porphyria (AIP) — all drugs for Acute Intermittent Porphyria (AIP) →
- Hereditary Coproporphyria (HCP) — all drugs for Hereditary Coproporphyria (HCP) →
Sponsor
Alnylam Pharmaceuticals — full company profile →
Who can join
16 and older, any sex, with Acute Hepatic Porphyria or Hepatic Porphyrias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic RNA Delivery for COVID and Other Diseases.
Dobrowolski C, Paunovska K, Hatit MZC, Lokugamage MP, et al · · 2021 · cited 46× · PMID 33661555 · DOI 10.1002/adhm.202002022
Verify or expand the search:
- PubMed search for NCT03547297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Hepatic Porphyria
Currently open trials in the same condition.
- NCT05344599 — Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome · active not recruiting
- NCT04883905 — ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) · recruiting
Other Alnylam Pharmaceuticals trials
Trials by the same sponsor.
- NCT07535606 — A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · Phase 1 · recruiting
- NCT07463846 — A Study to Evaluate ALN-2232 in Participants With Obesity · Phase 1, PHASE2 · recruiting
- NCT07223203 — TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos · Phase 3 · recruiting
- NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
- NCT07358078 — DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03547297 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alnylam Pharmaceuticals
- Last refreshed: 25 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03547297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing